Karyopharm Therapeutics | KPTI - 销售收入



金融业
股票价格
USD
资产
USD 108.42M
现金及等价物
USD 60.54M
销售成本
USD 1.48M
流动资产
USD 103.15M
流动负债
USD 92.06M
债务
USD 299.23M
股息收益率
0
EBIT
USD -17.84M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -2.22
股本和储备
USD -292.93M
销售毛利
USD 32.6M
债务利息支出
USD 12.62M
利息收入
USD -0.15
贷款资金
USD 278.22M
市值
USD 1.07B
净收入
USD -102.2M
营业费用
USD 51.92M
营业利润
USD -17.84M
普通股股本
USD 18.31M
税前利润
USD -39.9M
销售收入
USD 34.08M
销售和管理费用
USD 9.56M
股票
USD 4.04M
贸易债权人
USD 4M
应收帐款人
USD 26.18M


销售 更改 日
AbbVie USD 15B 1.62B 2026-03
Abbott USD 11.16B 300M 2026-03
Amgen USD 8.62B 1.28B 2026-03
AstraZeneca USD 15.29B 213M 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
GlaxoSmithKline GBP 7.63B 991M 2026-03
Incyte USD 1.27B 240M 2026-03
J&J USD 24.1B 500M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Merck USD 16.29B 110M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Novartis USD 13.11B 226M 2026-03
Novartis USD 13.11B 750M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Takeda JPY 1.19T 80B 2025-12
Tectonic Therapeutic USD 0 0 2024-12
TG Therapeutics USD 192.57M 30.87M 2025-12
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Xencor USD 28.24M 7.24M 2025-12